TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Lexicon Pharmaceuticals
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

A clinical study demonstrated sotagliflozin's potential benefits for heart failure patients with preserved ejection fraction (HFpEF) without diabetes, showing significant improvements in cardiac structure, function, and quality of life.

Insights
LXRX   positive

The company presented promising clinical trial results for sotagliflozin, showing potential therapeutic benefits in a new patient population, which could expand the drug's market and commercial potential